IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Trinity Biotech plc and Advises Investors with Losses to Contact the Firm

LOS ANGELES--()--Lundin Law PC (http://lundinlawpc.com/) announces that it is investigating claims against Trinity Biotech plc (“Trinity” or the “Company”) (Nasdaq: TRIB) concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.

The investigation concerns Trinity’s October 4, 2016 announcement that it will withdraw its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer on the advice of the U.S. Food & Drug Administration. The Company also stated that it would reduce spending by nearly 85% and that it would close a Swedish facility, eliminating 40 jobs. When this information was announced, shares of Trinity fell in value.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

Contacts

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/